XRAY Maintained by Piper Sandler -- Price Target Raised to $14.0

Piper Sandler has maintained a Neutral rating for Dentsply Sirona (XRAY) and raised its price target from $13.00 to $14.00, signaling cautious optimism for the company's future. Despite current unprofitability, XRAY is considered 26.3% undervalued according to its GF Value™ of $18.99, and insider activity shows net buying, suggesting potential for recovery. The company, a major dental equipment manufacturer, has a moderate GF Score™ of 59/100, with strong valuation but weak growth.